Winton Group’s Corcept Therapeutics CORT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-19,905
| Closed | -$2.27M | – | 852 |
|
|
2025
Q1 | $2.27M | Sell |
19,905
-3,770
| -16% | -$229K | 0.14% | 166 |
|
|
2024
Q4 | $1.19M | Buy |
23,675
+4,520
| +24% | +$237K | 0.08% | 233 |
|
|
2024
Q3 | $886K | Sell |
19,155
-16,684
| -47% | -$593K | 0.06% | 348 |
|
|
2024
Q2 | $1.16M | Sell |
35,839
-4,433
| -11% | -$121K | 0.08% | 182 |
|
|
2024
Q1 | $1.01M | Buy |
40,272
+24,775
| +160% | +$585K | 0.07% | 249 |
|
|
2023
Q4 | $503K | Buy |
15,497
+22
| +0.1% | +$604 | 0.04% | 314 |
|
|
2023
Q3 | $422K | Sell |
15,475
-7,248
| -32% | -$210K | 0.03% | 328 |
|
|
2023
Q2 | $506K | Sell |
22,723
-88,850
| -80% | -$2.05M | 0.04% | 311 |
|
|
2023
Q1 | $2.42M | Buy |
111,573
+230
| +0.2% | +$5.04K | 0.15% | 168 |
|
|
2022
Q4 | $2.26M | Buy |
111,343
+7,323
| +7% | +$184K | 0.15% | 176 |
|
|
2022
Q3 | $2.67M | Sell |
104,020
-25,324
| -20% | -$678K | 0.17% | 139 |
|
|
2022
Q2 | $3.08M | Buy |
129,344
+12,196
| +10% | +$266K | 0.16% | 158 |
|
|
2022
Q1 | $2.64M | Sell |
117,148
-1,422
| -1% | -$30.2K | 0.14% | 177 |
|
|
2021
Q4 | $2.35M | Sell |
118,570
-3,754
| -3% | -$76.2K | 0.14% | 177 |
|
|
2021
Q3 | $2.41M | Buy |
122,324
+9,589
| +9% | +$201K | 0.13% | 128 |
|
|
2021
Q2 | $2.48M | Buy |
112,735
+7,383
| +7% | +$164K | 0.13% | 112 |
|
|
2021
Q1 | $2.51M | Sell |
105,352
-5,157
| -5% | -$138K | 0.14% | 83 |
|
|
2020
Q4 | $2.89M | Sell |
110,509
-247,769
| -69% | -$5.22M | 0.21% | 44 |
|
|
2020
Q3 | $6.24M | Sell |
358,278
-187,868
| -34% | -$2.99M | 0.2% | 74 |
|
|
2020
Q2 | $9.19M | Sell |
546,146
-86,653
| -14% | -$1.22M | 0.24% | 51 |
|
|
2020
Q1 | $7.52M | Sell |
632,799
-22,595
| -3% | -$280K | 0.2% | 124 |
|
|
2019
Q4 | $7.93M | Buy |
655,394
+595,403
| +992% | +$8.29M | 0.11% | 312 |
|
|
2019
Q3 | $848K | Buy |
59,991
+35,412
| +144% | +$435K | 0.01% | 907 |
|
|
2019
Q2 | $274K | Buy |
+24,579
| New | +$274K | 0.01% | 928 |
|
|
2019
Q1 | – | Sell |
-12,545
| Closed | -$168K | – | 1095 |
|
|
2018
Q4 | $168K | Sell |
12,545
-7,193
| -36% | -$95.1K | ﹤0.01% | 826 |
|
|
2018
Q3 | $277K | Sell |
19,738
-2,956
| -13% | -$41.3K | 0.01% | 845 |
|
|
2018
Q2 | $357K | Sell |
22,694
-13,029
| -36% | -$227K | 0.01% | 762 |
|
|
2018
Q1 | $588K | Buy |
+35,723
| New | +$662K | 0.02% | 696 |
|
Other funds holding CORT
ISL
PA
Winton Group's CORT Position: Q2 2025 in Review
Winton Group sold out of Corcept Therapeutics (CORT) in Q2 2025, closing a stake of 19,905 shares — an estimated $2.27M sold.
Winton Group first reported a position in CORT in Q1 2018 and held it in 28 quarters. The position peaked at $9.19M in Q2 2020. 422 funds tracked by Wall St. Rank hold CORT as of Q2 2025.
- Winton Group reported no remaining Corcept Therapeutics position as of Q2 2025 after selling out during the quarter.
- Winton Group sold 19,905 Corcept Therapeutics shares in Q2 2025, an estimated $2.27M.
- Winton Group first reported a position in Corcept Therapeutics in Q1 2018 and held it in 28 quarters.
- Winton Group's Corcept Therapeutics position peaked at $9.19M in Q2 2020.
- 422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2025.
Based on Winton Group's 13F filing for Q2 2025, filed 14 Aug 2025.